| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wei Lv, Ying Xu. Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods. European journal of medicinal chemistry. vol 45. issue 3. 2010-07-22. PMID:20053484. |
acetylcholinesterase (ache) has become an important drug target and its inhibitors have proved useful in the symptomatic treatment of alzheimer's disease. |
2010-07-22 |
2023-08-12 |
Not clear |
| Fenglei Huang, Yali F. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Current clinical pharmacology. vol 5. issue 2. 2010-07-21. PMID:20156150. |
a review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of alzheimer's disease, in healthy subjects and patients. |
2010-07-21 |
2023-08-12 |
human |
| Fenglei Huang, Yali F. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Current clinical pharmacology. vol 5. issue 2. 2010-07-21. PMID:20156150. |
galantamine is a reversible acetylcholinesterase inhibitor for the treatment of alzheimer's disease. |
2010-07-21 |
2023-08-12 |
human |
| David S Greenberg, Debra Toiber, Amit Berson, Hermona Sore. Acetylcholinesterase variants in Alzheimer's disease: from neuroprotection to programmed cell death. Neuro-degenerative diseases. vol 7. issue 1-3. 2010-07-21. PMID:20173328. |
acetylcholinesterase variants in alzheimer's disease: from neuroprotection to programmed cell death. |
2010-07-21 |
2023-08-12 |
Not clear |
| Hongxin Dong, Carla M Yuede, Carolyn A Coughlan, Keely M Murphy, John G Csernansk. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain research. vol 1303. 2010-07-13. PMID:19799879. |
donepezil, an acetylcholinesterase inhibitor, is an approved drug for the treatment of alzheimer's disease (ad). |
2010-07-13 |
2023-08-12 |
mouse |
| Tsuneyoshi Ota, Hitoshi Shinotoh, Kiyoshi Fukushi, Tatsuya Kikuchi, Koichi Sato, Noriko Tanaka, Hitoshi Shimada, Shigeki Hirano, Michie Miyoshi, Heii Arai, Tetsuya Suhara, Toshiaki Iri. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clinical neuropharmacology. vol 33. issue 2. 2010-07-08. PMID:19935404. |
estimation of plasma ic50 of donepezil for cerebral acetylcholinesterase inhibition in patients with alzheimer disease using positron emission tomography. |
2010-07-08 |
2023-08-12 |
Not clear |
| Sang-Hoon Lee, Jin-Sook Park, Se-Kwon Kim, Chang-Bum Ahn, Jae-Young J. Chitooligosaccharides suppress the level of protein expression and acetylcholinesterase activity induced by Abeta25-35 in PC12 cells. Bioorganic & medicinal chemistry letters. vol 19. issue 3. 2010-07-06. PMID:19097785. |
clinical applications of acetylcholinesterase (ache) inhibitors are widespread in alzheimer's sufferers in order to activate central cholinergic system and alleviate cognitive deficits by inhibiting the hydrolysis of acetylcholine. |
2010-07-06 |
2023-08-12 |
Not clear |
| Torsten Geissler, Wolfgang Brandt, Andrea Porzel, Dagmar Schlenzig, Astrid Kehlen, Ludger Wessjohann, Norbert Arnol. Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorganic & medicinal chemistry. vol 18. issue 6. 2010-07-06. PMID:20176490. |
inhibition of acetylcholinesterase (ache) and therefore prevention of acetylcholine degradation is one of the most accepted therapy opportunities for alzheimer s disease (ad), today. |
2010-07-06 |
2023-08-12 |
Not clear |
| Thomas Leyhe, Nadine Hoffmann, Elke Stransky, Christoph Lask. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. The international journal of neuropsychopharmacology. vol 12. issue 10. 2010-06-29. PMID:19580698. |
alzheimer's disease (ad) can be treated with inhibitors of the enzyme acetylcholinesterase (ache). |
2010-06-29 |
2023-08-12 |
Not clear |
| Elio Scarpini, Filippo Cogiamania. Alzheimer's disease: from molecular pathogenesis to innovative therapies. Expert review of neurotherapeutics. vol 3. issue 5. 2010-06-29. PMID:19810962. |
current standard treatment of alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. |
2010-06-29 |
2023-08-12 |
Not clear |
| Takemi Handa, Rajesh G Katare, Yoshihiko Kakinuma, Mikihiko Arikawa, Motonori Ando, Shiro Sasaguri, Fumiyasu Yamasaki, Takayuki Sat. Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. Journal of cardiac failure. vol 15. issue 9. 2010-06-29. PMID:19879468. |
to develop an alternative therapy with a clinically available drug, we examined the chronic effect of oral donepezil, an acetylcholinesterase inhibitor against alzheimer's disease, on cardiac remodeling and survival with a murine model of volume-overloaded chf. |
2010-06-29 |
2023-08-12 |
mouse |
| G Waldema. Donepezil in the treatment of patients with Alzheimer's disease. Expert review of neurotherapeutics. vol 1. issue 1. 2010-06-25. PMID:19811041. |
donepezil is the most widely used acetylcholinesterase inhibitor licensed for symptomatic treatment of mild-to-moderate alzheimer's disease. |
2010-06-25 |
2023-08-12 |
Not clear |
| S Moghul, D Wilkinso. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert review of neurotherapeutics. vol 1. issue 1. 2010-06-25. PMID:19811047. |
use of acetylcholinesterase inhibitors in alzheimer's disease. |
2010-06-25 |
2023-08-12 |
Not clear |
| S Moghul, D Wilkinso. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert review of neurotherapeutics. vol 1. issue 1. 2010-06-25. PMID:19811047. |
the three new acetylcholinesterase inhibitors licensed to treat alzheimer's disease (donepezil, rivastigmine and galantamine) have provided clinicians with a major impetus to their desire to diagnose and treat this lethal disease. |
2010-06-25 |
2023-08-12 |
Not clear |
| D G Wilkinso. Galantamine: a new treatment for Alzheimer's disease. Expert review of neurotherapeutics. vol 1. issue 2. 2010-06-23. PMID:19811027. |
galantamine appears to be an effective treatment for alzheimer's disease comparable with the other acetylcholinesterase inhibitors in improving cognition and function with growing evidence for its effects on behavior and caregiver burden. |
2010-06-23 |
2023-08-12 |
Not clear |
| Vildan Alptüzün, Michaela Prinz, Verena Hörr, Josef Scheiber, Krzysztof Radacki, Adyary Fallarero, Pia Vuorela, Bernd Engels, Holger Braunschweig, Ercin Erciyas, Ulrike Holzgrab. Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases. Bioorganic & medicinal chemistry. vol 18. issue 5. 2010-06-15. PMID:20149667. |
approved drugs for the treatment of alzheimer's disease belong to the group of inhibitors of the acetylcholinesterase (ache) and nmda receptor inhibitors. |
2010-06-15 |
2023-08-12 |
Not clear |
| Narihiro Toda, Tsugio Kaneko, Hiroshi Koge. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Chemical & pharmaceutical bulletin. vol 58. issue 3. 2010-06-15. PMID:20190429. |
development of an efficient therapeutic agent for alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. |
2010-06-15 |
2023-08-12 |
mouse |
| Narihiro Toda, Tsugio Kaneko, Hiroshi Koge. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Chemical & pharmaceutical bulletin. vol 58. issue 3. 2010-06-15. PMID:20190429. |
to date, acetylcholinesterase (ache) inhibitors have been clinically effective drugs for the palliative treatment of alzheimer's disease, but their clinical efficacy is limited, mainly due to their adverse effects on peripheral organs. |
2010-06-15 |
2023-08-12 |
mouse |
| Eugenia Rota, Patrizia Ferrero, Rita Ursone, Giuseppe Migliarett. Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice. Bioinformation. vol 2. issue 2. 2010-06-09. PMID:18188418. |
short term response is predictive of long term response to acetylcholinesterase inhibitors in alzheimer's disease: a starting point to explore bayesian approximation in clinical practice. |
2010-06-09 |
2023-08-12 |
Not clear |
| Eugenia Rota, Patrizia Ferrero, Rita Ursone, Giuseppe Migliarett. Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice. Bioinformation. vol 2. issue 2. 2010-06-09. PMID:18188418. |
this study was aimed at identifying, in 203 patients with alzheimer's disease followed during long-term treatment with acetylcholinesterase inhibitors (cheis), the predictive factors of the clinical response among cognition (mmse), functioning (badl and iadl) measures and age and gender at the baseline (t0). |
2010-06-09 |
2023-08-12 |
Not clear |